Knowledge Intensive Services
Collaboration for new therapies: maximizing funding and innovation
How do the public and private sectors collaborate on European medicines R&D and how can we increase the synergies that stem from the involvement of these sectors? ...
Breaking the time capsule: Life Sciences in 2010 and today
CRA’s Life Sciences Practice team recently analyzed past predictions of industry trends and compared them to what has occurred in the past decade, identified influencing factors and success drivers of these trends, and applied them to current industry predictions to outline what needs t...
Chris Dunn approved as a full member of the Association of Business Mentors
Chris Dunn writes...I'm so pleased that my application to become a full member of the Association of Business Mentors has been accepted. ...
A Unique Blend of Consulting, Coaching, and Mentoring To Help You Grow the Smart Way
Chris Dunn Consulting recently turned 9 years old. Of course, a lot has changed over the years but one thing has not. The company's purpose. ...
The new Chris Dunn Consulting website is now live
Exciting for Chris of course, but why should you care? Because hopefully, you'll find some interesting and original content on how to drive business growth the smart way. ...
How does rare disease prevalence impact drug pricing in England?
This article was originally published in PharmaPhorum. In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in reimbursement decisions among payers in England, comparing assessment...
World Orphan Drug Congress Europe 2022
CRA is a proud sponsor of the congress. Cecile Matthews and Bhavesh Patel present their session titled “Project LEOPARD (Long-term Evolution & Outlook for Patient Access in Rare Disease): Initial findings on what the future holds.” Michele Pistollato presents h...
Part 2: Low-priced oncology disruptors - The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Part II of this article was originally published in PharmaPhorum.
Part 1: Low-priced oncology disruptors - The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Part I of this article was originally published in PharmaPhorum.
Google, Apple, BT and Arm executives to speak at the world’s first Cambridge Tech Week
The week will centre Cambridge and the UK as a global leader in artificial intelligence and deep technology, showcasing world renowned research and innovation ...